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Endoglin is an accessory receptor for TGFβ and can associate with Alk5 or Alk2. Although prior studies indicated that endoglin and Alk5 were
not directly involved in epithelial–mesenchymal transformation (EMT) in the heart, the expression pattern of endoglin prompted a re-examination.
We here show that loss of endoglin expression mediated by either antisense DNA or siRNA results in a direct perturbation of EMT and reduced
expression of EMT markers including slug, runx2, RhoA, and latrophilin-2. An examination of BrdU incorporation shows that, while endoglin
regulates proliferation at an early stage, reduced endothelial cell proliferation does not account for the loss of mesenchyme. As Alk5 interacts with
endoglin, we utilized siRNA and a specific inhibitor, HTS466284 (HTS), to perturb this receptor as well. Alk5 inhibition produced similar effects
to the inhibition of endoglin. There was a reduction in mesenchymal cell formation and loss of EMT marker expression similar to that seen with
endoglin. Alk5 kinase inhibition produced a similar loss of EMT marker expression but showed a contrasting upregulation of the proliferation and
remodeling markers, Cyclin B2 and β-catenin. Alk5 and endoglin both mediate endothelial cell proliferation in younger explants but, by stage 16,
loss of endoglin no longer alters proliferation rates. These data show that both Alk5 and endoglin are directly involved in the process of EMT, that
they interact with both TGFβ-regulated activation and invasion pathways and that the roles of these receptors change during cardiac development.
© 2006 Elsevier Inc. All rights reserved.Keywords: EMT; TRβRI; TGFbeta 3; Runx2Introduction
EMT is the process by which epithelial cells disaggregate and
change shape while invading and migrating into three-dimen-
sional environments to form a specific organ or structure or
break down an epithelial barrier. EMT occurs during metastatic
cancer and throughout development (Thompson et al., 2005). In
the developing heart, the atrioventricular (AV) canal and the
outflow tract (OT) region undergo an EMT to form the valves of
the heart (Eisenberg and Markwald, 1995; Runyan et al., 1992).
In these areas, the cardiac jelly (extracellular matrix) separates
the myocardium from the endothelium and molecular cues from
the myocardium signal the endothelium to activate (Krug et al.,
1985; Markwald et al., 1977; Runyan and Markwald, 1983).
During the activation step, endothelial cells organized in a
single-cell layer lose cell–cell contacts, undergo hypertrophy⁎ Corresponding author. Fax: +1 520 626 2097.
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(Bolender et al., 1980; Crossin and Hoffman, 1991; Krug et al.,
1985). In the chick at stage 17, activated endothelial cells begin
to invade the cardiac jelly, becomingmesenchymal cells. Studies
suggest that only a subset of activated endothelial cells become
mesenchymal cells (Krug et al., 1985; Runyan et al., 1990;
Wunsch et al., 1994). Among the many molecules shown to
regulate the EMT process, there is a common element among
them involving the transforming growth factor beta (TGFβ)
family (Potts and Runyan, 1989; Potts et al., 1991; Nakajima et
al., 1993; Barnett et al., 1994; Brown et al., 1996; Brown et al.,
1999).
The primary members of the TGFβ family are the ligands
TGFβ1, 2 and 3 (Azhar et al., 2003). Studies in chick embryos
show that they have distinct roles in mediating EMT and that
there is some specificity of receptors in mediating isoform-
specific activities (Boyer et al., 1999; Boyer and Runyan, 2001).
Transforming growth factor receptors include a series of serine–
threonine kinases collectively identified as Type I receptors or
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Type I and Type II receptors form a complex that can signal
through Smads and other signal transduction molecules (Wrana,
1998). Larger receptors include TGFβRIII (β-glycan) and the
membrane glycoprotein, endoglin (CD105), but these have
traditionally been presented as accessory proteins interacting
with the Type I/Type II complex (Cheifetz et al., 1992; Lopez-
Casillas et al., 1991). Endoglin binds TGFβ1, TGFβ3, activin-
A, bone morphogenetic protein (BMP)-7 and BMP-2 in the
presence of the respective ligand binding receptors (Barbara et
al., 1999). Endoglin is present in the AV canal of the chick at the
time of EMT but the functional significance of this observation
could not be demonstrated at the time (Vincent et al., 1998).
Sorensen et al. (2003) showed that endoglin null mice have
hypocellular cardiac cushions in the AV canal. However, based
on collagen gel assays, they concluded that the role of endoglin
in EMT was likely indirect.
In humans and mice, endoglin expression is present as two
isoforms that differ in the amino acid composition of their
cytoplasmic tails, i.e. L-endoglin and S-endoglin (Bellon et al.,
1993; Gougos and Letarte, 1990; Perez-Gomez et al., 2005).
Human L-endoglin abrogates the inhibitory action of TGFβ in
the proliferation of promonocytic cells while S-endoglin
partially inhibits proliferation (Lastres et al., 1996). In humans,
mutations of endoglin are associated with hereditary hemor-
rhagic telangiectasia type 1 (HHT1), a disease characterized by
blood vessel malformation (Berg et al., 1996; Guttmacher et al.,
1995; McAllister et al., 1994, 1995). In mice, endoglin-null
mice (Eng−/−) showed arterio-venous malformation (HHT
phenotype) and heart defects associated with valve formation
and heart septation (Arthur et al., 2000; Bourdeau et al., 1999;
Sorensen et al., 2003).
Most studies of endoglin are targeted towards its role as a
marker of endothelial cell proliferation in angiogenesis. In this
process, endoglin modulates proliferation by interacting with
the TBRI receptors, activin receptor-like kinase 1 (Alk1) and
Alk5 (Franzen et al., 1993; Wrana et al., 1994). Activation of
Alk1 by TGFβ induces endothelial cell proliferation while
TGFβ activation of Alk5 inhibits migration and proliferation of
endothelial cells. Studies performed with embryonic endothelial
cells from heterozygous endoglin mice (Eng+/−) showed that
endoglin balances endothelial cell proliferation by promoting
Alk1 and inhibiting the Alk5 pathway when it binds to TGFβ3
in association with TBRII (Blanco et al., 2005; Lebrin et al.,
2004). However, Alk5-deficient endothelial cells are not only
defective in their TGFβ/Alk5 responses but in their TGFβ/Alk1
responses (Goumans et al., 2003). In these studies, Alk5 proved
to be necessary for the recruitment of Alk1 into the TGFβ
receptor complex. Alk5 kinase activity was crucial for the
activation of Alk1 during endothelial cell proliferation during
angiogenesis. Studies by Lai et al. (2000) showed a requirement
for Alk2 in EMT and suggested that Alk5 was not involved in
this process although it was present in the AV canal. In light of
our findings concerning endoglin function, we chose to re-
examine Alk5 as well.
In the present study, we re-investigate the roles of endoglin
and Alk5 in the process of EMT in the AV cushion. Our resultsshow that blocking endoglin or Alk5 inhibits EMT in cultured
AV explants. As endoglin regulates endothelial proliferation by
interaction with Alk5 and Alk1, we explored whether the loss of
mesenchymal cells was due to a decrease of cell proliferation.
We determined that endoglin does mediate endothelial pro-
liferation in the AV cushion but a role in EMT regulation can be
distinguished. Loss of Alk5 expression by treatment with
siRNA decreases cell proliferation and mesenchymal cell
numbers, while inhibition of Alk5 kinase activity decreases
mesenchymal cell numbers at all stages and has differential
effects on endothelial cell proliferation at different develop-
mental stages. These data suggest that the role of Alk5 changes
during development. Loss of EMT markers argues that both
endoglin and Alk5 mediate the process of EMTand suggest that
they interact together in the AV canal.
Material and methods
In situ hybridization
Chick embryos (stages 14 to 18) were collected and fixed overnight at 4 °C
in 4% paraformaldehyde. Embryos were processed for in situ hybridization as in
the Harland Xenopus protocol (Harland, 1991). Antisense RNAwas transcribed
with T3 RNA polymerase and the sense probe with the T7 RNA polymerase
from the same subclone used for siRNa cocktail (see siRNA treatment of AV
canal explants).
Collagen gel culture
Collagen gel explants were prepared as previously described (Runyan and
Markwald, 1983, Romano and Runyan, 1999). Briefly, rat tail collagen in
acidic, diluted Medium 199 (M199, pH 4.0, 0.1% concentration) was
polymerized by addition of 10× M199 and 10× NaHCO3 (2.2 g/100 ml) in
16 mm multiwell dishes (Nunc). After polymerization each gel was rinsed once
with 300–500 μl M199 and then incubated with complete medium (M199, 1.0%
chick serum, ITS supplement (Gibco)) and Antibiotic–Antimicotic (Gibco) to
condition the gel until use. AV canal segments were collected from staged chick
embryos into Tyrode's solution (Sigma) and transferred into 5-ml polystyrene
round-bottom tubes for each treatment. Excess medium was decanted from the
gel surface and heart segments were placed on the gel surface by pipette. After
attachment overnight, cultures were treated with added medium. A video
showing gel preparation and AV canal dissection is available upon request from
the authors.
Cell counts
To determine the effects of the treatments in EMT, we counted all
mesenchymal cells produced by each AV explant (cells observed below the gel
surface using Hoffman Differential Contrast microscopy). Mesenchymal cell
numbers were averaged per treatment for 10–30 explants. The control mean was
set as 100% and the mean and standard error for each treatment was compared to
the control value determined for that experiment. A similar comparison was
performed to evaluate cellular activation (cells separated from each other in the
endothelium but not invaded into the gel matrix). To determine the effects of the
treatments in cell proliferation, cells on the surface of the gels incorporating
BrdU in the nucleus were counted and compared to all DAPI-stained nuclei seen
on the gel surface. Cells within the myocardial explant and within the gel matrix
were ignored. Again, the mean for controls cultures was set to 100% and
comparisons within each experiment were compared to that value.
siRNA treatment of AV canal explants
siRNA was made by two methods. For endoglin, Silencer siRNA
construction kits from Ambion (#1625 and 1620) were used to make both a
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sequence) was used. To design ALK5 siRNA targets, we used the Ambion
website (http://www.ambion.com/techlib/misc/siRNA_finder.html) to select
specific sequences. For an endoglin target sequence, we used the RNAi target
sequence prediction of the BBSRC ChickEST Database (http://www.chick.
umist.ac.uk/). To the selected target sequence, we added a T7 promoter sequence
and used the same Ambion siRNA construction kit.
The siRNA cocktail for endoglin was made from a fragment of 488 bp of the
chicken endoglin complete sequence AY702002 corresponding to base pairs
1033 to 152 (extracellular domain). RNA was extracted from stage 15 AV and
cDNA was synthesized after DNase treatment. A PCR reaction replicated the
endoglin fragment. This piece was subcloned into pBluescript II SK (±) vector
using XhoI and EcoRI. Top10 bacteria were transformed with this construct and
sequencing was performed to confirm the endoglin sequence. siRNA cocktail
was transfected into AV explants with oligofectamine from Invitrogen. The
siRNA (10 nM) and the oligofectamine (6 μl) were diluted separately in 100 μl
of M199 1× medium. They were mixed together and incubated for 15 min at
room temperature to allow siRNA/oligofectamine complexes to form.
For treatment, AV explants in M199 medium were collected in 100 μl of
medium and added to the mixture of siRNA and oligofectamine. Explants in
300μl of themixturewere incubated at 37 °C, 5%CO2 for 45min to 1 h. Explants
were then placed on conditioned collagen gels and incubated under the same
conditions overnight. The next day, a boost was given to the explants with 10 nM
of siRNA solution and incubated at 37 °C, 5% CO2 for 45 min to 1 h and the
siRNA solution was replaced with complete media. For transfection of siRNA
derived from 21 bp RNA (target sequence), we used 4 μl of the siPORT NeoFX
(Ambion) or oligofectamine and the rest of the treatment was identical. 24 h after
initial transfection and incubation, explants cultures were fixed for 1/2 h, with 4%
paraformaldehyde at room temperature and washed with PBS. Fixed cultures
were used for cell counts. Similar explants used for real-time PCR were
homogenized in 1ml of Trizol and stored at −80 °C or processed immediately for
RNA isolation.
The siRNA target sequence for endoglin was 5′-AAGGTCTGGCG-
CTTCCGCTTC-3′; for Alk5, 5′-AAGGAACTACTTTGAAGGATT-3′ and for
control siRNA, a scrambled 21 oligonucleotide template containing the same
number of the different bases of the endoglin siRNA target that did not blast to
any gene in the chicken genome, 5′-AGACTGTCGCGTGCTCTGTCC-3′.
BrdU staining and DNA fragmentation
After siRNA treatment and boost, AV explants on collagen gels were
incubated with 100 μM of BrdU (BD Biosciences Pharmingen) in complete
medium for 3–4 h at 37 °C, 5% CO2. Then, washed with PBS four times for
5 min and fixed with 4% paraformaldehyde for 1/2 h at room temperature.
Explants were rinsed three times with PBS and washed four times for 5 min at
room temperature. They were permeabilized with 0.1% Triton X-100/PBS for
15 min and treated with 25–30 μl of DNAse (0.1 U/μl) at 37 °C for 1/2 h.
Explants were washed five times for 5 min at room temperature and blocked
with 1% BSA/0.1% Triton X-100/PBS for 1 h at room temperature or overnight
at 4 °C. Explants were incubated with 2.5 ng/μl of anti-BrdU antibody for 1 h at
room temperature or overnight at 4 °C. After antibody treatment, they wereTable 1
Real-time PCR primers
Primer Forward sequence
Endoglin 5′-CAACAACCAAGGGCTGGGG-3′
ALK5 5′-GCGGCCGCATTACAATGTTAC-3′
Runx2 5′-AACCCAAACTTGCCCAACCAGA
Slug 5′-GCAGACCCACTCGGATGTGAA-3
Latrophilin-2 5′-CTGAGGGAACCGACAGCTAC-3′
RhoA 5′-GTTGGCTTTGTGGGATAC-3′
VE-cadherin 5′-TTCACAGCTCTTCACCCAGGCA
β-Catenin 5′-TCCCCCATTGAGAATATCCA-3′
Cyclin B2 5′-AGGGGTGGAGAATGCCGTGA-3′
Fibulin 2 5′-CAGCCAGGAGTGTGCCAATGTT
Id1 5′-CGCTGCTGTATGACATGAAGGGwashed with 0.1% Triton X-100 in PBS five times for 10 min and incubated for
1–2 h with 1:200 dilution of anti-mouse secondary antibodyMCR546 (2 mg/ml)
at room temperature. Explants were washed with 0.1% Triton X-100 in PBS five
times for 10 min. They were rinsed with PBS three times and then incubated
with 300 μl of DAPI (0.1 μg/ml) for 20 min. Samples were rinsed with PBS
three times and then mounted on slides with Polymount. BrdU-labeled cells
were counted and photographed using a Deltavision Deconvolution microscope.
Apoptosis was measured using a DNA Ladder Assay PCR Kit designed for
the detection of nucleosomal ladders in apoptotic cells (Maxim Biotech, Inc.,
San Francisco, cat. # APO-DNA1). Fifteen stage 16 AV explants were treated
with endoglin antisense, thirteen with reverse sense and thirteen untreated and
incubated at 37 °C, 5% CO2 for 45 min in 300 μl of M199 medium containing
the respective treatments. A positive control sample of 13 AV explants was
incubated at 42 °C in M199 medium for 45 min. After this incubation period,
explants were transferred to collagen gels and incubated for 8 h at 37 °C, 5%
CO2. DNA from each of the samples was extracted with the BDtract Genomic
DNA Isolation Kit (Maxim Biotech, Inc., cat. # SA-4002). Analysis was carried
out according to the protocol instructions of APO-DNA1 Kit. Equal amounts of
genomic DNAwere used for the ligation of the adaptors and the PCR reaction.
The positive control of the kit was used to compare the levels of apotosis in the
experimental samples. 10 μl from each PCR reaction corresponding to each of
the respective treatments and the kit's positive control were loaded into each
well of a 2% agarose.
Quantitative real-time PCR
AV explants were homogenized with Trizol (Invitrogen) and processed for
RNA isolation according to the manufacturer's protocol. RNA was DNased
(Turbo DNA-free Ambion Kit #1907) and cDNA was synthesized using an
iScript cDNA synthesis kit (# 170-8891, BioRad). cDNAwas measured with a
Mini-Fluorometer (Turner Biosystems) after staining with OliGreen ssDNA
Quantitation (Molecular Probes) and equal aliquots of cDNA of control and
experimental samples were added to triplicate reaction mixtures. Real-time PCR
reactions were carried out using primers in Table 1, the super mix Platinum
SYBR Green qPCR Super Mix UDG (Invitrogen) and the Rotor Gene 3000
System from Corbett Research. Analysis of the data was carried out using the
Rotor Gene 6 software provided by the manufacturer.
Inhibition of Alk5 kinase activity
AV explants from stage 15 and 16 embryos were dissected in Tyrode's,
rinsed in M199 1× medium and placed on preconditioned collagen gels. The
explants were incubated at 37 °C, 5% CO2 for 8 h to allow them to adhere to the
collagen. 100 nM of HTS466284 (HTS; gift of Dr. Daruka Mahadevan) in
300 μl of complete medium was added to the experimental explants at 8 h (solid
inhibitor was dissolved in DMSO and was serially diluted in M199 to reach the
final concentration). The timing of HTS exposure allowed for normal
endothelial outgrowth from the explants but was added at a time when there
was little or no mesenchymal cell invasion into the gel. Explants received a final
DMSO concentration of 0.5–2 nl/ml. Controls were treated with an equalReverse sequence
5′-TGGAGATGGGACGGGTATGC-3′
5′-TGGCCTGTCTCGAGGAATCA-3′
-3′ 5′-GCCTCCAAACGGACTCATCCAT-3′
′ 5′-CGCAGCAGCCAGATTCCTCA-3′
5′-CGGAGAGTCTCTGAGGTTGG-3′
5′-CAGAAATGCTTCACTTCCG-3′
-3′ 5′-CCCCAAGCAGCAATTTTGAGGA-3′
5′-GTTGCAACACCCTCATTCCT-3′
5′-TGCCAGGTCCTTTCGTAGCCTT-3′
-3′ 5′-CGGAAAGTGCAAAGAATGCCCT-3′
-3′ 5′CAGGTCCCAGATGTAGTCGATCAC-3′
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After 16–18 h, the inhibitor was replaced by with complete medium containing
BrdU in the cultures needed for cell counting and complete medium in the
cultures needed for RNA extraction. After 3 to 4 h of incubation, the cultures
were processed for BrdU staining and/or RNA extraction respectively (as
above).
Results
Developmental expression of endoglin in the AV canal
In humans and mice endoglin expression occurs during the
time when the heart valves are formed and it is expressed in the
endothelium as well as in the mesenchyme of the AV canal
(Bourdeau et al., 2000; Qu et al., 1998). Studies of endoglin
expression in the chick by immunohistochemistry showed that
endoglin protein levels in the AV canal progressively decreasedFig. 1. Endoglin expression by in situ hybridization in the heart at the time of EMT. (
embryo. (B) A stage 16 embryo shows a decrease in endoglin expression in the AV ca
the AV canal at stage 17. (D) Stage 15 embryo reacted with an endoglin sense probe
endothelium of the outflow tract (OTe) region and in the proepicardium (PE) where E
including the posterior cardinal veins (pCV), intersegmantal vessels (ISv) between th
stage 18 shows endoglin expression in the mesenchyme (mes) and the endotheliumin the myocardium between developmental stages 14 to 16 and
then rose at stage 17 in the endothelium and cushions (Vincent
et al., 1998). We explored by in situ and real-time PCR whether
expression levels of endoglin mRNA changed in concert with
protein levels during development in the AV canal. Our in situ
data show that endoglin mRNA expression is detected in the
endothelium at stage 15 (earliest stage examined), decreases at
stage 16 and then increases at stage 17 when mesenchymal
cells first start invading the cushions in the AV canal (Figs. 1A,
B and C). Endoglin expression in the heart is present in the
endothelium of the outflow tract region and the pro-epicardium
(Fig. 1E) where EMT occurs. The pro-epicardium gives rise to
the coronary vessels of the heart (Mikawa and Fischman, 1992;
Olivey et al., 2004; Poelmann et al., 1993). In the chick, we
also see endoglin expression in the developing blood vessels of
the brain and of the rest of the body (Fig. 1F). These data agreeA) Endoglin is expressed in the endothelium (AVe) of the AV canal in a stage 15
nal compared to stages 15 and 17 embryos. (C) Endoglin expression increases in
shows no expression of endoglin. (E) Stage 17 embryo shows expression in the
MT occurs. (F) Embryo at stage 17 shows endoglin expression in blood vessels
e somites and the microvessels (mv) in the head. (G) Section of the AV canal at
of the Av canal.
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is expressed in the cushions and major and minor developing
blood vessels (Bourdeau et al., 1999). Endoglin mRNA was
also localized in the mesenchymal cells of the AV canal at
stages 17 and 18 (Fig. 1G) as well as in the mesenchymal cells
of the OT region. We confirmed the apparent decrease of
endoglin expression at stage 16 by real-time PCR using RNA
isolated from staged AV explants. These results show that
endoglin mRNA expression levels decrease between stages 14
and 16 and increase at stage 17 (Fig. 2A). The expression of
endoglin in the AV canal (endothelial and mesenchymal cells),
OT and proepicardium is consistent with a role for endoglin in
the process of EMT.
Blocking endoglin expression reduces the number of
mesenchymal cells in AV explant cultures
As endoglin expression is present in the AV canal during
EMT, we examined whether blocking endoglin expression
would affect either the activation process before EMT or the
number of mesenchymal cells produced in vitro. We used both
antisense DNA and siRNA endoglin to block endoglin
expression in AVexplants (stages 13–17) and measure changes
in the number of activated endothelia or invaded mesenchymal
cells within the collagen gel matrix. AV explants were
transfected with either antisense DNA or siRNA for 45 min at
37 °C, 5% CO2. The explants were then cultured on collagen
gels overnight and fixed after 18–24 or 48 h of incubation with
antisense DNA and for 24 h with siRNA. Results with antisense
DNA were qualitatively and quantitatively similar to siRNA in
showing a loss of mesenchyme at 18–24 h (Figs. 2B, C and 3)
but by 48 h mesenchymal cell numbers were indistinguishable
from controls (data not shown).
Cultures treated with siRNA were examined to see whether
changes in activation (endothelial cell separation) were
coincident with changes in mesenchymal cell formation.
Endoglin siRNA decreased the number of mesenchymal cells
significantly compared to controls by 90% at stage 15, 40% atFig. 2. Endoglin expression changes during development but is required for
EMT. (A) Levels of endoglin mRNA expression in AV canal segments measured
by real-time PCR. Dissected AV canal segments were collected for mRNA
analysis. Endoglin expression levels decreased at stage 16 and increased at stage
17 when mesenchymal cells begin to invade the cushions. Data represent
duplicate experiments with three repetitive reactions per stage. Data was
normalized to total cDNA in each reaction. Changes are graphed relative to stage
14 and relative values are displayed above each bar. (B) Cells from antisense
endoglin treated explants (60 pooled explants, stages 15–17 at time of
collection) showed a loss of mesenchymal and activated cells (40% reduction)
after 24 h compared to control oligonucleotides. (C) Staged explants were
specifically examined for activation and invasion after siRNA endoglin
treatment. Loss of endoglin produced the greatest loss of mesenchyme in
stage 15 explants but a loss was observed in explants collected from each of the
other stages. Activation of endothelial cells on the surface was unaffected in
stage 16 explants and significant in both the younger and older explants. siRNA
effects on mesenchymal and activated cells are compared to effects of control
siRNA. Activated cells are defined as cells without attached neighboring cells
remaining on the surface of the gels. A minimum of 15 explants were counted
for each siRNA experiment. Error bars indicate the SEM. Significant p values,
smaller than 0.05, are indicated by an asterisk (*) in each panel.stage 16, and 50% at stage 17 (Figs. 2C and 3). A loss of
activation was observed at stages 15 and 17 but not at stage 16
(Fig. 2C). At stages 15 and 16 there was a relatively greater loss
of mesenchymal cell number than a reduction in activation.
Loss of mesenchyme in the cultures can occur by a direct
inhibition of EMT, cell death in endothelial or mesenchymal
cells or a reduced rate of proliferation. To explore programmed
cell death, we performed a DNA fragmentation assay between
endoglin antisense DNA-treated explants and explants treated
with the control oligonucleotide. There was little DNA
fragmentation and no difference between treated and control
cultures (data not shown). We conclude that cell death is not a
viable explanation for the loss of mesenchymal cells in these
Fig. 3. Blocking endoglin expression by either Antisense DNA or siRNA decreases the number of mesenchymal cells. Images of collagen explant cultures were taken
with a plane of focus just beneath the endothelial layer to show mesenchymal cells within the gel. (A) Control, culture treated with reverse sense, endoglin
oligodeoxynucleotides show a typical distribution of mesenchymal cells after 24 h of treatment. (B) Endoglin antisense DNA decreased the number of mesenchymal
cells in cultured AVexplants after 24 h of treatment. (C) Control siRNA treatment with normal mesenchymal cell invasion in stage 16 cultured AVexplants. (D) siRNA
endoglin decreased the number of mesenchymal cells in cultured AV explants. The endothelial monolayer produces the out of focus polygonal pattern and the dark
mass in each picture is the myocardial portion of the explant. Arrows mark selected mesenchymal cells in each micrograph.
425M.E. Mercado-Pimentel et al. / Developmental Biology 304 (2007) 420–432cultures. While changes in cell proliferation are explored below,
the decrease in number of mesenchymal cells by both antisense
and siRNA argues that endoglin has a functional role in the
formation of the mesenchymal cell population.
Endoglin regulates genes known to function in the process of
EMT
To begin to understand how endoglin functions in the EMT
process during heart valve development, we performed initial
gene microarrays to identify potential endoglin targets during
EMT in the AV canal. AV explants from chicken embryos of
stages 15, 16, and 17 were treated with either antisense
endoglin or reverse sense sequence. The microarray data
identified endoglin numerous ESTs as well as several well-
known genes involved in the process of EMT including β-
catenin and RhoA. β-catenin is considered to be a crosslink
between TGFβ2 and Wnt-signaling pathways in the induction
of the AV canal EMT in the mouse (Liebner et al., 2004) as well
as a gene regulated by Wnt-9a during mesenchymal cell
proliferation in the AV canal (Person et al., 2005). RhoA is
involved in the EMT process, regulated by TGFβ2 and TGFβ3
and it regulates β-catenin expression in the chick AV canal
(Tavares et al., 2006). Our previous work identified slug and
VE-cadherin as targets of TGFβ2 (Romano and Runyan, 2000).
Runx2, a TGFβ-related transcription factor, is expressed in theAV canal (Gitler et al., 2003) and blocking its expression
decreases the number of mesenchymal cells (unpublished data).
Latrophilin-2 is a G protein-coupled receptor involved in EMT
in the AV canal (Doyle et al., 2006). Fibulin-2 is an
extracellular matrix maker that is expressed by mesenchymal
cells in the AV cushions during EMT in the AV canal of the
mouse (Takeshi Tsuda et al., 2001).
Real-time PCR was used to determine whether loss of
endoglin expression in AV explants at stage 16 perturbs
expression of these markers. To examine whether changes in
marker expression were specific to AV canal endothelium
engaged in EMT, changes in selected markers were also
evaluated in ventricular explants. Real-time PCR measurement
showed that inhibition of endoglin expression by siRNA in the
AV canal down regulates expression of Runx2, slug, latrophilin-
2, Rho A, VE-cadherin, β-catenin, fibulin2 as well as cyclin B2
and Id1, two markers of cell proliferation (Fig. 4A). Ventricular
explants produced endothelia but not mesenchyme after 24 h in
culture (Supplementary Fig. 1) and showed an increase in Runx2
expression after loss of endoglin (data not shown). As formation
of a RISC complex and specific degradation of mRNA by
siRNA is not detectable in less than 10 h (unpublished data), we
examined loss of marker mRNA expression after treatment with
antisense DNA targeting endoglin mRNA at earlier time points
(Runyan et al., 2000). Real-time PCR measurement of selected
markers at 4 h and 8 h after treatment showed significant loss of
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at 8 h (Fig. 4B). While the change in marker expression at these
intervals does not determine whether endoglin directly or
indirectly regulates marker expression, it suggests that changesinmarker expression are the result of a loss of signal transduction
requiring endoglin.
Endoglin-mediated regulation of proliferation is stage-specific
Several studies showed that endoglin modulates the process
of endothelial cell proliferation and migration during angiogen-
esis. Lebrin and coworkers found that endoglin balances
signaling pathways between TGFβ/Alk1 and TGFβ/Alk5
(Lebrin et al., 2004). Endothelial cells that lack endoglin do
not proliferate because TGFβ/Alk1 signaling is reduced and
TGFβ/Alk5 signaling is increased creating an imbalance in cell
proliferation. Our results (above) show that blocking endoglin
expression decreases cyclin B2 expression in the AV canal and
confirm a role for endoglin in endothelial cell proliferation.
Therefore, we explored whether the decrease in mesenchymal
cell numbers was due to a decrease in cell proliferation.
Endoglin expression in AVexplants derived from stages 15 and
16 embryos was inhibited with siRNA and explants were
labeled with BrdU to measure the rate of endothelial cell
proliferation. Our results show that inhibition of endoglin
expression significantly reduced the number of BrdU-labeled
endothelial cells in stage 15 explants (Fig. 4C). However, older,
stage 16 explants had no significant change in endothelial cell
proliferation. This stage specificity is concomitant with a
change in protein levels (Vincent et al., 1998) and a change in
mRNA expression levels in the endothelium and mesenchyme
(Figs. 1A–C, G and 2A). Inhibition of endoglin expression at
both stages produced a decrease in the number of mesenchymal
cells (Fig. 2B). These data suggest that loss of mesenchymal cell
numbers at the earlier stage could be due to a changed rate of
proliferation but that reduced mesenchymal cell formation in the
older stage is not attributable to altered proliferation. These data
indicate that at stage 16 endoglin has distinct roles in endothelial
cell proliferation and EMT in the AV canal.Fig. 4. Inhibition of Endoglin expression decreases expression of EMT markers
but alters proliferation only in younger explants. (A) AV canal explants were
collected for measurement of mRNA levels after 24 h of treatment with endoglin
or control siRNA. Endoglin siRNA effectively inhibited expression of endoglin
and concomitantly reduced the TGFβ receptor Alk5, EMT-related markers
Runx2, Slug, Latrophilin-2, RhoA, and Fibulin 2. The endothelial and
mesenchymal cell proliferation markers, β-catenin, Id1 and cyclin B2, and an
endothelial cell adhesion marker, VE-cadherin, are also reduced after loss of
endoglin. The mean expression level for each marker in the control samples was
set at 1.0. (B) To explore loss of endoglin at earlier intervals, cultures (30
explants/treatment) were incubated with antisense DNA or control DNA and
examined at 4 and 8 h. Endoglin expression was reduced 90–95% at both time
points. These treatments blocked the expression of markers similarly to siRNA
and the effect was stronger at 8 h than at 4 h. Triplicate reactions were performed
for each gene and compared to control samples that were normalized to 1.0.
Error bars indicate the standard error of the mean. (C) Endoglin regulates
endothelial cell proliferation in younger explants but not in older explants. To
assess changes during development, heart explants were taken from various
stages of development. We noted a transition in responses between stage 15
(∼52 h) and stage 16 (∼55 h) embryos. Endothelial cell proliferation is reduced
in explants derived from stage 15 when endoglin expression is inhibited. Older
explants, closer to the onset of EMT in the AV canal (stage 16), show no change
in proliferation upon siRNA inhibition of endoglin. N=8 for each SEM bar.
*p<0.01, n.s.: not significant.
Fig. 5. Inhibition of Alk5 kinase activity does not affect significantly the rate of
endothelial cell proliferation in AV canal explants but it does block EMT. (A)
Alk5 kinase activity inhibited with 100 nM HTS does not significantly alter
endothelial cell proliferation in explants derived from either stage 15 or 16.
Stage 15 N=10 and stage 16 N=15. (B) Inhibition of Alk5 kinase activity by
HTS at both stages 15 and 16 reduces the number of mesenchymal cells in the
collagen gel matrix. N=13 for each bar. *p<0.01.
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Endoglin is known to interact with two TGFβ Type I
receptors, Alk1 and Alk5 (Blanco et al., 2005; Guerrero-Esteo
et al., 2002). It is recognized that TGFβ1 and TGFβ3 inhibit
endothelial cell proliferation through the Alk5 pathway
(Goumans et al., 2002). The interaction of endoglin with the
Alk5 and Alk1 pathways balances endothelial cell proliferation
by potentiating the Alk1 pathway and inhibiting the Alk5
pathway (Lebrin et al., 2004). We used 100 nM HTS, a
specific Alk5 kinase inhibitor (Singh et al., 2003), to block
Alk5 kinase activity in stages 15 and 16 AV explants and to
measure proliferation rate by incorporation of BrdU. Our
results show that inhibiting the kinase activity of Alk5 with
this specific inhibitor does not significantly change endothelial
cell proliferation in explants at either stage (Fig. 5A).
However, the number of mesenchymal cells decreased
significantly in both stages (Figs. 5B and 6A, B). This is
consistent with a role for Alk5 in mediating TGFβ stimulated
EMT. These results dissociate the number of mesenchymal
cells within the gels from cell proliferation.
Loss of Alk5 expression decreases proliferation rate and
mesenchymal cell number
As inhibition of kinase activity by HTS may not prevent
important intermolecular associations by Alk5 and the inhibitor
may also inhibit Alk4 kinase, we explored whether loss of Alk5
expression would similarly affect endothelial cell proliferation
and EMT in the AV canal. siRNA was used to inhibit Alk5
expression in stages 15 and 16 AV explants and cell
proliferation was measured by incorporation of BrdU. Results
showed that loss of Alk5 significantly decreased the rate of
endothelial cell proliferation (Fig. 7A) and the number of
mesenchymal cells in both stages (Fig. 7B). However, the
number of activated endothelial cells decreased at stage 15 but
not at stage 16 (Figs. 6C, D and 7B) as seen with endoglin
siRNA in both stages. These results confirm a requirement for
Alk5 in EMT but suggest that regulation of cell proliferation
and cell activation in the AV canal by Alk5 is more complex.
Blocking Alk5 expression and inhibiting its kinase activity
down-regulated the expression of EMT markers in the AV canal
We examined marker regulation to compare with the
endoglin data and to explore differences between loss of Alk5
and kinase inhibition. Real-time PCR was performed on stage
16 AV explants after siRNA (Fig. 7C) or HTS (Fig. 7D)
treatment overnight. The timing of HTS addition was chosen to
allow outgrowth of endothelia onto the collagen gel surface
prior to EMT and to approximate the time that functional
perturbation produced by siRNA would be expected to start.
Loss of EMT marker expression after each treatment was
similar to that seen after inhibition of endoglin expression and is
consistent with the model of endoglin–Alk5 interaction seen in
endothelia. Loss of Alk5 by siRNA decreased cyclin B2expression, consistent with BrdU incorporation (Fig. 7A).
However, inhibition of Alk5 kinase activity with HTS increased
the expression of cyclin B2 and β-catenin (Fig. 7D). This
contrasting regulation of two endothelial cell proliferation
markers by loss of Alk5 or inhibition of Alk5 kinase suggests
that Alk5 kinase activity is required to keep cell proliferation in
check or that HTS interacts with another kinase in the regulation
of these two markers.
Singh et al. (2003) showed that HTS had an IC50 of 60 nM for
Alk5. To demonstrate that HTS kinase inhibitor at 100 nM was
an appropriate intervention, a dose–response experiment was
undertaken. Using two EMT markers (Runx2 and Slug) and a
proliferation marker (Id1) under the same treatment protocol,
Fig. 6. Alk5 regulates the process of EMT in the AV canal. Both inhibition of Alk5 kinase activity with HTS or loss of Alk5 by siRNA blocks the invasion of
mesenchymal cells. Pictures are focused beneath the endothelial cell layer to show the presence of mesenchymal cells in the gels. (A) Control stage 16 AV explant
treated with DMSO demonstrates normal level of mesenchymal cells in the collagen matrix. (B) AV explant treated with the Alk5 kinase inhibitor has almost no
mesenchymal cell invasion. (C) Stage 16 explant treated with control siRNA has normal invasion of mesenchymal cells. (D) AV explant treated with Alk5 siRNA
blocked the invasion of mesenchymal cells into the collagen matrix. Mesenchymal cells are marked by arrowheads.
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marker. Runx2 showed a maximum inhibition of expression at
50 nM while Slug was maximally inhibited at 200 nM and Id1
was most strongly affected at 400 nM (Fig. 8). Differences in
inhibition were relatively small in the range of 50–200 nM. At
400 nM HTS, inhibition of Runx2 was no longer observed but
inhibition of slug and Id1 remained. The 400 nM dose was also
observed to completely block endothelial outgrowth from stage
16 explants when HTS was added to collagen gels prior to the
addition of explants (data not shown). Together, these results
suggest that ALK5 kinase is necessary for the regulation of
EMT and proliferation genes and that HTS is not a completely
specific inhibitor of Alk5 kinase activity.
Discussion
In the present study, we show evidence for the first time that
endoglin and Alk5, members of the TGFβ receptor family,
directly regulate the process of EMT in the AV canal. Loss of
endoglin or Alk5 expression or inhibition of Alk5 kinase
activity, each decrease the number of mesenchymal cells and
concomitantly down-regulate expression of EMT markers in
AV explants. We further show that changes in endoglin
expression in the AV canal during development coincide with
the acquisition of a role for endoglin in mediating EMT.
While changes in cell proliferation with the loss of endoglin
could account for the decrease of mesenchymal cells during
EMT, we found clear evidence in older explants that the
decrease in mesenchymal cell number is independent ofchanges in endothelial cell proliferation. DNA fragmentation
assays also showed that the loss of mesenchyme after inhibition
of endoglin expression was not due to programmed cell death.
Thus, endoglin appears to play a direct signal transduction role
in the regulation of EMT. We further show that changes in
endoglin expression in the AV canal during development
coincide with this role for endoglin in mediating EMT.
Together, these results suggest an interaction between Alk5
and endoglin in mediating EMT. Differences in cyclin B2 and
β-catenin expression between loss of endoglin and Alk5 kinase
activity suggest that the interaction is not exclusive.
These data vary significantly from published work on both
endoglin and Alk5. The endoglin-null mouse has cardiac
cushions that are acellular or hypocellular consistent with a role
in EMT but, in contrast to the data presented here, Sorensen
et al. (2003) found that AV explant cultures from these mice
were indistinguishable from controls at 48 h. We observed
significant differences in chick cultures at 24 h but saw a
recovery by 48 h. As our interventions may be temporally
limited, recovery in the chick cultures could correspond to
renewal of mRNA and protein expression, but this does not
explain the observation in murine cultures. We speculate that a
similar recovery may have also occurred in the mouse cultures
by the induction of a redundant mechanism. As there is no
apparent recovery in vivo, differences between extracellular
matrix substrates in vivo and in vitro may be significant. The
striking loss of mesenchymal cells in the cushions of the Eng−/−
mouse argues that endoglin may also function as a mediator of
EMT in mammals in vivo. Expression of endoglin in the AV
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group showed that endoglin expression is up-regulated during
heart septation and valve formation in humans in cushion tissue
mesenchyme at greater levels than the other TGFβ receptors
(Qu et al., 1998).Fig. 8. Alk5 kinase inhibitor, HTS, effects vary by dose, tissue developmental
stage and time of treatment. Stage 16 explants were treated with varying does of
HTS after 8 h in culture. This interval was selected to disrupt the process of EMT
at a time similar to the perturbation provided by siRNA treatment. Under these
conditions, the maximal inhibition of Runx2 was at 50 nM, for Slug at 200 nM
and 400 nM for Id1. These data suggest that 100 nM HTS is an appropriate dose
for comparison to siRNA treatment for endoglin and Alk5.Mutations in endoglin are associated with hereditary
hemorrhagic telangiectasia (HHT1) (McAllister et al., 1994;
1995). It is possible that the inhibition of EMT seen here with
loss of endoglin has a relationship to the etiology of the arterio-
venous malformations associated with HHT1. As noted by
Braverman et al. (1990) the formation of the lesions is
associated with a loss of peri-endothelial cells. It is not clear
that peri-endothelial cells are formed by EMT from the
endothelium but there is evidence to suggest that endothelial
cells “transdifferentiate” into vascular wall cells in a process
similar to the EMT seen in the heart (De Ruiter et al., 1997).
Angiogenic mechanisms include also an invasion and migration
of endothelial-derived cells similar to the EMT described here.
Reports that angiogenesis is reduced in endoglin heterozygote
mice and that endoglin is associated with cell migration of
endothelial cells may be relevant to both EMT and the etiologyFig. 7. Loss of Alk5 expression affects endothelial cell proliferation, invasion
and marker expression. (A) Alk5 siRNA treatment significantly decreased
endothelial BrdU incorporation in stage 15 and 16 explants compared to the
controls. (B) Alk5 siRNA significantly decreased the number of activated cells
in stage 15 explants but not stage 16 explants while decreasing the number of
mesenchymal cells in both stages. The loss of mesenchymal cells was greater
than the change in cell proliferation at each stage. (C) siRNA inhibition of Alk5
in stage 16 AV canals decreased mRNA expression of EMT markers including
endoglin, Runx2, slug, latrophilin-2, and RhoA. Cell adhesion marker VE-
cadherin and the proliferation markers β-catenin and Cyclin B2, were also
reduced by loss of ALK5. (D) In contrast to loss of Alk5 expression, inhibition
of Alk5 kinase activity by HTS (100 nM added 8 h after incubation) produced an
inhibition of EMTmarkers and an elevation of cell proliferation markers. Kinase
activity by this TGFβ receptor is part of the regulation of EMTand appears to be
keeping cell proliferation in check. Ten explants were counted for each lane in A
and B and *p<.05, error bars indicate SEM. Thirty explants were collected for
each treatment in C and D and error bars indicate the SEM of triplicate real-time
PCR measurements.
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(Conley et al., 2004; Jerkic et al., 2006).
Studies by Barnett and colleagues similarly suggested that
Alk5 does not regulate EMT in the AV cushion of the chick
heart. In the experiments of Lai et al. (2000), an antibody
against the extracellular domain of Alk5 (with a demonstrated
blocking activity in regulation of a PAI-1 reporter in mink lung
epithelial cells) failed to inhibit EMT in stages 13 to 18 AV
explants. As both inhibition of kinase activity and reduction in
expression of the molecule inhibit EMT in this study, the failure
of the antibody to inhibit EMT suggests that the extracellular
epitope recognized by the antibody is not a critical part of the
EMT signal. Additional studies by Desgrosellier et al. (2005)
using adenoviral constructs containing constitutively active
Alk5 (caAlk5) receptor were injected into the heart lumen of
stages 10–12 chick embryos. AV explants from these embryos
were cultured in collagen gels and overexpression of caAlk5
had no effect on mesenchymal cell numbers. The failure of
overexpression to induce added EMTsuggests a requirement for
a specific interaction. The caAlk5 construct was generated by
replacing threonine 204 of the GS domain in Alk5 with an
aspartic acid, which yields a product that has an increased
kinase activity (Labbe et al., 2000; Ward et al., 2002; Wieser et
al., 1995). However, it was shown by others that a constitutively
active human Alk5 with the same substitution (T204D) does not
interact with endoglin when co-transfected in COS-7 cells
(Guerrero-Esteo et al., 2002). One explanation for the inability
of caAlk5 to enhance EMT in the explants, despite an active
kinase domain, is its inability to interact with endoglin. Though
kinase inhibitor experiments suggest that Alk5 kinase activity is
important, the common regulation of EMT markers by the loss
of either Alk5 or endoglin is consistent with a requirement for
an interaction between these molecules.
There is a complexity of TGFβ signaling and receptor
activity in the AV canal that remains to be elucidated. We
previously showed that two distinct TGFβ signal transduction
pathways are involved in the induction of EMT. Inhibition of
TGFβ2 blocks endothelial cell separation and expression of
the zinc finger transcription factor, slug (Boyer et al., 1999;
Romano and Runyan, 2000). Inhibition of TGFβRIII receptor
in AV canal cultures similarly blocks cell separation and EMT
(Brown et al., 1999; Boyer et al., 1999; Boyer and Runyan,
2001). Inhibition of TGFβ3, TGFβRII or Alk2 all result in
cultures where endothelial cells are activated and separated
but are unable to invade the collagen gel matrix (Potts et al.,
1991; Brown et al., 1996; Boyer et al., 1999, 2001; Lai et al.,
2000; unpublished data). At its simplest level, these
molecules can be divided into two distinct and sequential
pathways using TGFβ2 for separation/activation and TGFβ3
for invasion. However, the present study appears to blur this
distinction.
In this study, loss of either endoglin or Alk5 yields images of
collagen gel cultures with rounded rather than fibroblastic
endothelial cells and the younger cultures tested with siRNA
towards Alk5 showed a loss of activation as well as cell
invasion. Though endoglin binds TGFβ3 with greater affinity
than TGFβ2 (Cheifetz et al., 1992), these data suggest arelationship with the TGFβ2-mediated activation process as
well. The regulation of slug was previously shown to be
TGFβ2-specific (Romano and Runyan, 1999) and loss of either
endoglin or Alk5 produced a loss of expression in the present
study. Measurements of activation and invasion showed an
effect by loss of endoglin on both steps of EMT. A recent
examination by microarray also supports this suggestion
(unpublished data). We found that genes and ESTs altered by
loss of endoglin were equally likely to be found in subsets of
markers specifically regulated by blocking antibodies to TGFβ2
or TGFβ3. The basis for an interaction between endoglin, Alk5
and the TGFβ2/TGFβRIII pathway is poorly understood but it
was shown in chondrocytes that endoglin and TGFβRIII
(betaglycan) could form a heteromeric complex independently
or involving TGFβRII (Parker et al., 2003). If such a complex is
formed in the developing heart as part of cell separation and
activation, it does not require TGFβRII, as separation, but not
invasion, proceeds normally when TGFβRII is inhibited (Boyer
and Runyan, 2001). The regulation of cell invasion markers
such as Runx2, latrophilin-2 by endoglin and Alk5 is consistent
with an interaction with the TGFβRII as a regulator of invasion
(Brown et al., 1996) but we note that Jiao et al. (2006) recently
demonstrated normal EMT in a mouse null for TGFβRII. The
recovery of cell invasion in mouse endoglin null explants and
the normal invasion seen in TGFβRII expants suggests that
such an association is not critical for invasion in vitro. It would
be interesting to determine whether the loss of both TGFβRII
and endoglin in the mouse would produce a failure of EMT
without the recovery seen in the endoglin null explants.
One explanation for the role of Alk5 in the EMT process is
based on the observation that Alk5 kinase activity is required for
TGFβ/Alk1 signaling for cell proliferation (Goumans et al.,
2003). Loss of Alk5 could inhibit Alk2-mediated EMT in a
similar manner. Observed differences in morphology argue
against this explanation but they do not disprove it. When we
explored a dose response to HTS using selected markers of
proliferation and EMT, we found a much different pattern of
regulation of Runx2, suggesting that the kinase inhibitor may be
interacting with other kinases as well despite the reported
specificity of the molecule (Singh et al., 2003). While the
inhibitor activity is consistent with loss of Alk5 by siRNA for
EMT markers, the differences in the dose response assays
between Id1 and Cyclin B2 and the contrast between the HTS
and siRNA treatments suggests that the role of Alk5 and other
kinases in regulation of proliferation is more complicated.
The data are most consistent with a role for endoglin at both
stages of EMT. First, as a modifier of TGFβ2 signal trans-
duction, in concert with Alk5 and TGFβRIII, at the cell
separation stage. Markers such as slug and VE-cadherin in
addition to morphology argue this point. Their sensitivity to loss
of endoglin and Alk5 as well as TGFβ2 supports an interaction.
TGFβ3 is required for cell invasion and involves both TGFβRII
and Alk2 in the chick (Potts et al., 1991; Brown et al., 1996;
Boyer et al., 1999; Lai et al., 2000; Boyer and Runyan, 2001).
RhoA is a marker of cell separation and invasion regulated by
both TGFβ2 and TGFβ3 (Tavares et al., 2006). It is sensitive to
both endoglin and Alk5 function in the present study. Runx2
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et al., 2003; Doyle et al., 2006) and they are also sensitive to the
perturbation of both endoglin and Alk5. Though changes in
marker expression during invasion could be consequences of
altered TGFβ2 signaling, a large majority of responses to TGFβ
isoforms in this system are isoform-specific. In light of the
potential for endoglin to interact with TGFβ3 (Cheifetz et al.,
1992) and Alk2 (Mo et al., 2002) and for Alk5 to interact with
endoglin (Blanco et al., 2005), the regulation of invasion
markers seen here is likely to be direct. Ongoing efforts to
characterize downstream markers of the separation and invasion
steps will be useful in resolving potential components of
receptor signaling complexes.
Acknowledgments
We thank Dr. Joey Barnett (Vanderbilt) and Drs. Antin,
Klewer, Camenisch and Heimark (Arizona) for useful discus-
sions during the conduct of this work. We thank Crystal
Willingham for technical assistance. This work was supported
by HL63926 from NHLBI and 0650076Z from the American
Heart Association, Pacific Mountain Affiliate. Dr. Mercado-
Pimentel was supported by NIEHS training grant ES007091.
Microscopy facilities were supported in part by NIEHS grant
ES06694.
Appendix A. Supplementary data
Supplementary data associated with this article can be found,
in the online version, at doi:10.1016/j.ydbio.2006.12.038.
References
Arthur, H.M., Ure, J., Smith, A.J., Renforth, G., Wilson, D.I., Torsney, E.,
Charlton, R., Parums, D.V., Jowett, T., Marchuk, D.A., Burn, J., Diamond,
A.G., 2000. Endoglin, an ancillary TGFbeta receptor, is required for
extraembryonic angiogenesis and plays a key role in heart development.
Dev. Biol. 217, 42–53.
Azhar, M., Schultz Jel, J., Grupp, I., Dorn, G.W., Meneton, P., Molin, D.G.,
Gittenberger-de Groot, A.C., Doetschman, T., 2003. Transforming growth
factor beta in cardiovascular development and function. Cytokine Growth
Factor Rev. 14, 391–407.
Barbara, N.P., Wrana, J.L., Letarte, M., 1999. Endoglin is an accessory protein
that interacts with the signaling receptor complex of multiple members of the
transforming growth factor-beta superfamily. J. Biol. Chem. 274, 584–594.
Barnett, J.V., Moustakas, A., Lin, W., Wang, X.F., Lin, H.Y., Galper, J.B., Maas,
R.L., 1994. Cloning and developmental expression of the chick type-II and
type-III TGF-beta receptors. Dev. Dyn. 199, 12–27.
Bellon, T., Corbi, A., Lastres, P., Cales, C., Cebrian, M., Vera, S., Cheifetz, S.,
Massague, J., Letarte, M., Bernabeu, C., 1993. Identification and expression
of two forms of the human transforming growth factor-beta-binding protein
endoglin with distinct cytoplasmic regions. Eur. J. Immunol. 23,
2340–2345.
Berg, J.N., Guttmacher, A.E., Marchuk, D.A., Porteous, M.E., 1996. Clinical
heterogeneity in hereditary haemorrhagic telangiectasia: are pulmonary
arteriovenous malformations more common in families linked to endoglin?
J. Med. Genet. 33, 256–257.
Blanco, F.J., Santibanez, J.F., Guerrero-Esteo, M., Langa, C., Vary, C.P.,
Bernabeu, C., 2005. Interaction and functional interplay between endoglin
and ALK-1, two components of the endothelial transforming growth factor-
beta receptor complex. J. Cell. Physiol. 204, 574–584.Bolender, D.L., Seliger, W.G., Markwald, R.R., 1980. A histochemical analysis
of polyanoinic compounds found in the extracellular matrix encountered by
migrating cephalic neural crest cells. Anat. Rec. 196, 401–412.
Bourdeau, A., Dumont, D.J., Letarte, M., 1999. A murine model of hereditary
hemorrhagic telangiectasia. J. Clin. Invest. 104, 1343–1351.
Bourdeau, A., Faughnan, M.E., Letarte, M., 2000. Endoglin-deficient mice, a
unique model to study hereditary hemorrhagic telangiectasia. Trends
Cardiovasc. Med. 10, 279–285.
Boyer, A.S., Runyan, R.B., 2001. TGFbeta type III and TGFbeta type II
receptors have distinct activities during epithelial–mesenchymal cell
transformation in the embryonic heart. Dev. Dyn. 221, 454–459.
Boyer, A.S., Ayerinskas, I.I., Vincent, E.B., McKinney, L.A., Weeks, D.L.,
Runyan, R.B., 1999. TGFbeta2 and TGFbeta3 have separate and sequential
activities during epithelial–mesenchymal cell transformation in the
embryonic heart. Dev. Biol. 208, 530–545.
Braverman, I.M., Keh, A., Jacobson, B.S., 1990. Ultrastrucuture and three-
dimensional organization of the telangiectases of hereditary hemorrhagic
telangiectasia. J. Invest. Dermatol. 95, 422–427.
Brown, C.B., Boyer, A.S., Runyan, R.B., Barnett, J.V., 1996. Antibodies to the
type II TGF-beta receptor block cell activation and migration during
atrioventricular cushion transformation in the heart. Dev. Biol. 174,
248–257.
Brown, C.B., Boyer, A.S., Runyan, R.B., Barnett, J.V., 1999. Requirement of
type III TGF-beta receptor for endocardial cell transformation in the heart.
Science 283, 2080–2082.
Cheifetz, S., Bellon, T., Cales, C., Vera, S., Bernabeu, C., Massague, J., Letarte,
M., 1992. Endoglin is a component of the transforming growth factor-beta
receptor system in human endothelial cells. J. Biol. Chem. 267,
19027–19030.
Conley, B.A., Koleva, R., Smith, J.D., Kacer, D., Zhang, D.W., Bernabeu, C.,
Vary, C.P.H., 2004. Endoglin controls cell migration and composition of
focal adhesions – function of the cytosolic domain. J. Biol. Chem. 279,
27440–27449.
Crossin, K.L., Hoffman, S., 1991. Expression of adhesion molecules during the
formation and differentiation of the avian endocardial cushion tissue. Dev.
Biol. 145, 277–286.
Desgrosellier, J.S., Mundell, N.A., McDonnell, M.A., Moses, H.L., Barnett, J.V.,
2005. Activin receptor-like kinase 2 and Smad6 regulate epithelial-
mesenchymal transformation during cardiac valve formation. Dev. Biol.
280, 201–210.
De Ruiter, M.C., Poelmann, R.E., Van Munsteren, J.C., Mironov, V., Markwald,
R.R., Gittenberger-de-Groot, A.C., 1997. Embryonic endothelial cells
transdifferentiate into mesenchymal cells expressing smooth muscle actins
in vivo and in vitro. Circ. Res. 80, 444–451.
Doyle, S.E., Scholz, M.J., Greer, K.A., Hubbard, A.D., Darnell, D.K., Antin,
P.A., Klewer, S.E., Runyan, R.R., 2006. Latrophilin-2 is a novel
component of the epithelial–mesenchymal transition within the atrioven-
tricular canal of the embryonic chicken heart. Dev. Dyn. 235, 3213–3221.
Eisenberg, L.M., Markwald, R.R., 1995. Molecular regulation of atrioventri-
cular valvuloseptal morphogenesis. Circ. Res. 77, 1–6.
Franzen, P., ten Dijke, P., Ichijo, H., Yamashita, H., Schulz, P., Heldin, C.H.,
Miyazono, K., 1993. Cloning of a TGF beta type I receptor that forms a
heteromeric complex with the TGF beta type II receptor. Cell 75, 681–692.
Gitler, A.D., Lu, M.M., Jiang, Y.Q., Epstein, J.A., Gruber, P.J., 2003. Molecular
markers of cardiac endocardial cushion development. Dev. Dyn. 228,
643–650.
Gougos, A., Letarte, M., 1990. Primary structure of endoglin, an RGD-
containing glycoprotein of human endothelial cells. J. Biol. Chem. 265,
8361–8364.
Goumans, M.J., Valdimarsdottir, G., Itoh, S., Rosendahl, A., Sideras, P., ten
Dijke, P., 2002. Balancing the activation state of the endothelium via two
distinct TGF-beta type I receptors. EMBO J. 21, 1743–1753.
Goumans, M.J., Valdimarsdottir, G., Itoh, S., Lebrin, F., Larsson, J., Mummery,
C., Karlsson, S., ten Dijke, P., 2003. Activin receptor-like kinase (ALK)1 is
an antagonistic mediator of lateral TGFbeta/ALK5 signaling. Mol. Cell 12,
817–828.
Guerrero-Esteo, M., Sanchez-Elsner, T., Letamendia, A., Bernabeu, C., 2002.
Extracellular and cytoplasmic domains of endoglin interact with the
432 M.E. Mercado-Pimentel et al. / Developmental Biology 304 (2007) 420–432transforming growth factor-beta receptors I and II. J. Biol. Chem. 277,
29197–29209.
Guttmacher, A.E., Marchuk, D.A., White Jr., R.I., 1995. Hereditary hemorrhagic
telangiectasia. N. Engl. J. Med. 333, 918–924.
Harland, R.M., 1991. In situ hybridization: an improved whole-mount method
for Xenopus embryos. Methods Cell Biol. 36, 685–695.
Jerkic, M., Rodriguez-Barbero, A., Prieto, M., Toporsian, M., Penicacho,
M., Rivas-Elena, J.V., Obreo, J., Wang, A., Perez-Barriocanal, F.,
Arevalo, M., Letarte, M., Lopez-Novoa, J.M., 2006. Reduced angiogenic
responses in adult endoglin heterozygous mice. Cardiovasc. Res. 69,
845–854.
Jiao, K., Langworthy, M., Batts, L., Brown, C.B., Moses, H.L., Baldwin, H.S.,
2006. TGFβ signaling is required for atrioventricular cushion mesenchyme
remodeling during in vivo cardiac development. Development 133,
4585–4593.
Krug, E.L., Runyan, R.B., Markwald, R.R., 1985. Protein extracts from early
embryonic hearts initiate cardiac endothelial cytodifferentiation. Dev. Biol.
112, 414–426.
Labbe, E., Letamendia, A., Attisano, L., 2000. Association of Smads with
lymphoid enhancer binding factor 1/T cell-specific factor mediates
cooperative signaling by the transforming growth factor-beta and wnt
pathways. Proc. Natl. Acad. Sci. U. S. A. 97, 8358–8363.
Lai, Y.T., Beason, K.B., Brames, G.P., Desgrosellier, J.S., Cleggett, M.C., Shaw,
M.V., Brown, C.B., Barnett, J.V., 2000. Activin receptor-like kinase 2 can
atrioventricular cushion transformation. Dev. Biol. 222, 1–11.
Lastres, P., Letamendia, A., Zhang, H., Rius, C., Almendro, N., Raab, U., Lopez,
L.A., Langa, C., Fabra, A., Letarte, M., Bernabeu, C., 1996. Endoglin
modulates cellular responses to TGF-beta 1. J. Cell Biol. 133, 1109–1121.
Lebrin, F., Goumans, M.J., Jonker, L., Carvalho, R.L., Valdimarsdottir, G.,
Thorikay, M., Mummery, C., Arthur, H.M., ten Dijke, P., 2004. Endoglin
promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduc-
tion. EMBO J. 23, 4018–4028.
Liebner, S., Cattelino, A., Gallini, R., Rudini, N., Iurlaro, M., Piccolo, S.,
Dejana, E., 2004. {beta}-Catenin is required for endothelial–mesenchymal
transformation during heart cushion development in the mouse. J. Cell Biol.
166, 359–367.
Lopez-Casillas, F., Cheifetz, S., Doody, J., Andres, J.L., Lane, W.S., Massague,
J., 1991. Structure and expression of the membrane proteoglycan
betaglycan, a component of the TGF-beta receptor system. Cell 67,
785–795.
Markwald, R.R., Fitzharris, T.P., Manasek, F.J., 1977. Structural development of
endocardial cushions. Am. J. Anat. 148, 85–119.
McAllister, K.A., Grogg, K.M., Johnson, D.W., Gallione, C.J., Baldwin, M.A.,
Jackson, C.E., Helmbold, E.A., Markel, D.S., McKinnon, W.C., Murrell, J.,
et al., 1994. Endoglin, a TGF-beta binding protein of endothelial cells, is the
gene for hereditary haemorrhagic telangiectasia type 1. Nat. Genet. 8,
345–351.
McAllister, K.A., Baldwin, M.A., Thukkani, A.K., Gallione, C.J., Berg, J.N.,
Porteous, M.E., Guttmacher, A.E., Marchuk, D.A., 1995. Six novel
mutations in the endoglin gene in hereditary hemorrhagic telangiectasia
type 1 suggest a dominant-negative effect of receptor function. Hum. Mol.
Genet. 4, 1983–1985.
Mikawa, T., Fischman, D.A., 1992. Retroviral analysis of cardiac morpho-
genesis: discontinuous formation of coronary vessels. Proc. Natl. Acad.
Sci. U. S. A. 89, 9504–9508.
Mo, J.Y., Fang, S.J., Chen, W., Blobe, G.C., 2002. Regulation of ALK-1
signalling by the nuclear receptor LXR beta. J. Biol. Chem. 277,
50788–50794.
Olivey, H.E., Compton, L.A., Barnett, J.V., 2004. Coronary vessel development:
the epicardium delivers. Trends Cardiovasc. Med. 14, 247–251.
Parker, W.L., Goldring, M.B., Philip, A., 2003. Endoglin is expressed on human
chondrocytes and forms a heteromeric complex with betaglycan in a ligand
and type II TGF beta receptor independent manner. J. Bone Miner. Res. 18,
289–302.
Perez-Gomez, E., Eleno, N., Lopez-Novoa, J.M., Ramirez, J.R., Velasco, B.,
Letarte, M., Bernabeu, C., Quintanilla, M., 2005. Characterization of murine
S-endoglin isoform and its effects on tumor development. Oncogene 24,
4450–4461.Person, A.D., Garriock, R.J., Krieg, P.A., Runyan, R.B., Klewer, S.E., 2005.
Frzb modulates Wnt-9a-mediated beta-catenin signaling during avian
atrioventricular cardiac cushion development. Dev. Biol. 278, 35–48.
Poelmann, R.E., Gittenberger-de Groot, A.C., Mentink, M.M., Bokenkamp, R.,
Hogers, B., 1993. Development of the cardiac coronary vascular
endothelium, studied with antiendothelial antibodies, in chicken–quail
chimeras. Circ. Res. 73, 559–568.
Potts, J.D., Runyan, R.B., 1989. Epithelial-mesenchymal transformation in the
embryonic heart can be mediated, in part, by transforming growth factor
beta. Dev. Biol. 134, 392–401.
Potts, J.D., Dagle, J.M., Walder, J.A., Weeks, D.L., Runyan, R.B., 1991.
Epithelial-mesenchymal transformation of embryonic cardiac endothelial
cells is inhibited by a modified antisense oligodeoxinucleotide to
transforming growth factor beta 3. Proc. Natl. Acad. Sci. U.S.A. 88,
1516–1520.
Qu, R., Silver, M.M., Letarte, M., 1998. Distribution of endoglin in early human
development reveals high levels on endocardial cushion tissue mesenchyme
during valve formation. Cell Tissue Res. 292, 333–343.
Romano, L.A., Runyan, R.B., 1999. Slug is a mediator of epithelial–
mesenchymal cell transformation in the developing chicken heart. Dev.
Biol. 212, 243–254.
Romano, L.A., Runyan, R.B., 2000. Slug is an essential target of TGFbeta2
signaling in the developing chicken heart. Dev. Biol. 223, 91–102.
Runyan, R.B., Markwald, R.R., 1983. Invasion of mesenchyme into three-
dimensional collagen gels: a regional and temporal analysis of interaction in
embryonic heart tissue. Dev. Biol. 95, 108–114.
Runyan, R.B., Potts, J.D., Sharma, R.V., Loeber, C.P., Chiang, J.J., Bhalla, R.C.,
1990. Signal transduction of a tissue interaction during embryonic heart
development. Cell Regul. 1, 301–313.
Runyan, R.B., Potts, J.D., Weeks, D.L., 1992. TGF-beta 3-mediated tissue
interaction during embryonic heart development. Mol. Reprod. Dev. 32,
152–159.
Singh, J., Chuaqui, C.E., Boriack-Sjodin, P.A., Lee, W.C., Pontz, T., Corbley,
M.J., Cheung, H.K., Arduini, R.M., Mead, J.N., Newman, M.N., Papadatos,
J.L., Bowes, S., Josiah, S., Ling, L.E., 2003. Successful shape-based virtual
screening: the discovery of a potent inhibitor of the type I TGFbeta receptor
kinase (TbetaRI). Bioorg. Med. Chem. Lett. 13, 4355–4359.
Sorensen, L.K., Brooke, B.S., Li, D.Y., Urness, L.D., 2003. Loss of distinct
arterial and venous boundaries in mice lacking endoglin, a vascular-specific
TGFbeta coreceptor. Dev. Biol. 261, 235–250.
Takeshi Tsuda, H.W., Rupert Timpl, Mon-Li Chu, 2001. Fibulin-2 expression
marks transformed mesenchymal cells in developing cardiac valves, aortic
arch vessels, and coronary vessels. Dev. Dyn. 222, 89–100.
Tavares, A.L., Mercado-Pimentel, M.E., Runyan, R.B., Kitten, G.T., 2006.
TGFbeta-mediated RhoA expression is necessary for epithelial–mesench-
ymal transition in the embryonic chick heart. Dev. Dyn. 235, 1589–1598.
Thompson, E.W., Newgreen, D.F., Tarin, D., 2005. Carcinoma invasion and
metastasis: a role for epithelial-mesenchymal transition. Cancer Res. 65,
5991–5995.
Vincent, E.B., Runyan, R.B., Weeks, D.L., 1998. Production of the transforming
growth factor-beta binding protein endoglin is regulated during chick heart
development. Dev. Dyn. 213, 237–247.
Ward, S.M., Desgrosellier, J.S., Zhuang, X., Barnett, J.V., Galper, J.B., 2002.
Transforming growth factor beta (TGFbeta) signaling via differential
activation of activin receptor-like kinases 2 and 5 during cardiac
development. Role in regulating parasympathetic responsiveness. J. Biol.
Chem. 277, 50183–50189.
Wieser, R., Wrana, J.L., Massague, J., 1995. GS domain mutations that
constitutively activate T beta R-I, the downstream signaling component in
the TGF-beta receptor complex. EMBO J. 14, 2199–2208.
Wrana, J.L., 1998. TGF-beta receptors and signalling mechanisms. Miner
Electrolyte Metab. 24, 120–130.
Wrana, J.L., Attisano, L., Wieser, R., Ventura, F., Massague, J., 1994.
Mechanism of activation of the TGF-beta receptor. Nature 370, 341–347.
Wunsch, A.M., Little, C.D., Markwald, R.R., 1994. Cardiac endothelial
heterogeneity defines valvular development as demonstrated by the diverse
expression of JB3, an antigen of the endocardial cushion tissue. Dev. Biol.
165, 585–601.
